Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Exchange Rate Effect (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Exchange Rate Effect for 11 consecutive years, with $5000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 125.0% year-over-year to $5000.0, compared with a TTM value of $20000.0 through Dec 2025, up 281.82%, and an annual FY2025 reading of $20000.0, up 281.82% over the prior year.
  • Exchange Rate Effect was $5000.0 for Q4 2025 at Karyopharm Therapeutics, up from $2000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $242000.0 in Q3 2021 and bottomed at -$454000.0 in Q2 2022.
  • Average Exchange Rate Effect over 5 years is -$28050.0, with a median of -$18000.0 recorded in 2024.
  • The sharpest move saw Exchange Rate Effect soared 1323.53% in 2021, then crashed 609.38% in 2022.
  • Year by year, Exchange Rate Effect stood at -$135000.0 in 2021, then skyrocketed by 193.33% to $126000.0 in 2022, then dropped by 29.37% to $89000.0 in 2023, then crashed by 122.47% to -$20000.0 in 2024, then surged by 125.0% to $5000.0 in 2025.
  • Business Quant data shows Exchange Rate Effect for KPTI at $5000.0 in Q4 2025, $2000.0 in Q3 2025, and $8000.0 in Q2 2025.